TGF - beta Type II Receptor Anomaly and of Its Functional Restoration in Osteosarcoma Cell Lines.
- Author:
Kwan Hee LEE
;
Sang Soo OH
;
Young Deog CHA
;
Suk Myun KO
;
In Suk OH
;
Joung Yoon LEE
;
Sung Jin KIM
- Publication Type:Original Article
- Keywords:
Osteosarcoma;
Gene Therapy;
TGF - beta type ll receptor
- MeSH:
Cell Line*;
Genetic Therapy;
Luciferases;
Osteosarcoma*;
Transfection
- From:The Journal of the Korean Orthopaedic Association
1998;33(3):914-919
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
TGF-p receptor mutation is now considered as one of the carcinogenic process of many tumors. To evaluate whether there is an abnormality in TGF-p type II receptor in osteosarcoma cell lines, we performed Northern analysis, cross-linking assay, luciferase activity and TGF-p growth inhibition assay in four osteosarcoma cell lines: G292, U202, HOS and SaOS. We also transfected the tumor cells with normal TGF-p type II receptor sequence to find if there is a possibility of gene therapy in osteosarcoma. In Northern analysis, Type II receptor expressions were decreased at SaOS, U202 and HOS cell lines. In cross-linking assay, all four cell lines didnt show type II receptor at their cell surface. The growth of these tumor cells were not suppressed by TGF-p. From these findings, we concluded that the normal production of TGF-p type II receptor was impaired in osteosarcoma. The transfection of these tumor cells with normal type II receptor sequence restored growth inhibition by TGF-p. This means even though TGF-p type II receptor is abnormal in osteosarcoma, we can restore its function by transfection of normal sequence. We think that the TGF-p type Il receptor gene therapy can be one of the treatment method for osteosarcoma in the future.
